New hope for women with Tough-to-Treat cervical cancer
NCT ID NCT07051486
Summary
This study is testing an experimental drug called SHR-A1811 for women with advanced cervical cancer that has returned or spread and has stopped responding to standard treatments. The trial will enroll 60 participants to see how well the drug shrinks tumors and controls the cancer. The main goal is to measure the response rate and see how long the treatment keeps the disease in check.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT OR METASTATIC CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fujian Cancer Hospital
RECRUITINGFuzhou, Fujian, 350011, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Shandong University Qilu Hospital
RECRUITINGJinan, Shandong, 250063, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.